Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
AstraZeneca Wins FDA Approval for Imfinzi-Padcev Combo in Bladder Cancer
AstraZeneca Wins FDA Approval for Imfinzi-Padcev Combo in Bladder Cancer
Read also
Cardiff Oncology's Onvansertib Earns FDA Fast Track for Colorectal Cancer
FDA granted Fast Track designation to Cardiff Oncology's onvansertib combination for RAS-mutated metastatic colorectal cancer after Phase 2 results.
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
Johnson & Johnson will acquire Ollin Biosciences for up to $3.3bn, adding OLN324, a Phase III antibody candidate for wet AMD and diabetic macular oedema.
Glenmark Launches Generic Axitinib in US as Cancer Drug Shares Rise 2%
Glenmark launched authorized generic axitinib tablets in the US for kidney cancer, entering a market where INLYTA sales reached $538.4 million in 12 months.
Lilly to Acquire Calytrix Bio for Up to $1.5B in Mutant CALR Antibody Deal
Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody targeting mutant calreticulin in rare blood disorders.